A Proof-Of-Concept Clinical Trial of a Novel KCNQ Potentiator in Major Depressive Disorder
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2019
Price : $35 *
At a glance
- Drugs Retigabine (Primary)
- Indications Major depressive disorder
- Focus Proof of concept; Therapeutic Use
- Acronyms MDD
- 20 Dec 2016 Status changed from recruiting to completed.
- 13 Apr 2016 Planned End Date changed from 1 Feb 2016 to 1 Jan 2017.
- 13 Apr 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Jan 2017.